Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Iodipamide is a water-soluble radiographic contrast agent primarily used for cholecystography and intravenous cholangiography to visualize the gallbladder and biliary ducts. After intravenous administration (often as iodipamide meglumine), it is rapidly taken up by the liver and secreted into bile within 10–15 minutes. The high iodine content of iodipamide makes it radio-opaque on x-ray imaging, allowing clear visualization of the hepatic and common bile ducts as well as the gallbladder. Most of the administered dose is eliminated in feces via bile; about 10% is excreted renally[1][2][3][4][6]. Its mechanism of action relies on its ability to absorb x-rays due to its iodine atoms rather than interaction with biological targets.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on iodipamide.